Skip to main content

Advertisement

Table 3 Drug efficacy in PDX models and OncoVee® MiniPDX capsules in mice

From: Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response

Model Location Pathology Chemotherapeutic or targeted drug (Regimen) TGI (%) Response in PDX TCGI(%) Response in MiniPDX
GAYW5 Stomach Poor/moderately differentiated AC, 80% S-1 (1) 95 ± 6 + 94 ± 15 +
GAYW7 Stomach Poorly differentiated AC, 90% S-1 (1) 86 ± 10 + 92 ± 3 +
GAYL1 Stomach Mucinous AC, 80% S-1 (1) 37 ± 10 13 ± 29
GAYB7 Stomach Poorly differentiated tubular AC, 70% S-1 (1) 44 ± 16 14 ± 20
GAYP53 Stomach Poor-moderately differentiated AC, 90% S-1 (1) 35 ± 10 17 ± 13
GASIL2 Stomach Moderately differentiated AC, 40% S-1 + Oxaliplatin (2) 29 ± 20 40 ± 17
GABSI3 Stomach Poorly differentiated AC, 80% S-1 + Oxaliplatin (2) 37 ± 12 75 ± 4 +
GAYP93 Stomach Moderately differentiated AC, 90% S-1 + Oxaliplatin(2) 27 ± 20 29 ± 15
GAYP97 Stomach Moderately differentiated AC, 90% S-1 + Oxaliplatin (2) 7 ± 29 9 ± 10
GAJ07 Stomach Poor-moderately differentiated AC, 50% Capecitabine + Oxaliplatin (3) 80 ± 3 + 35 ± 13
GASI80 Stomach Poorly differentiated AC, 80% Capecitabine + Oxaliplatin (3) 112 ± 3 + 50 ± 11 +
GASI05 Stomach Moderately differentiated AC, 40% Epirubicin + Capecitabine + Oxaliplatin (4) 97 ± 16 + 45 ± 23 +
GASAB3 Stomach Poorly differentiated AC, 90% Cisplatin + 5-FU + Docetaxel (5) 43 ± 17 17 ± 14
GAYP16 Stomach Poorly differentiated AC, 90% Cisplatin + 5-FU + Docetaxel (5) 32 ± 16 −13 ± 39
GAYP53 Stomach Poor-moderately differentiated AC, 90% Cisplatin + 5-FU + Docetaxel (5) 125 ± 3 + 50 ± 7 +
LULI02 Lung Poorly differentiated SCC, 98% Docetaxel (6) 97 ± 12 + 51 ± 7 +
LULI03 Lung Poorly differentiated AC, 98% Docetaxel (6) 12 ± 23 15 ± 10
LULI20 Lung Poorly differentiated AC, 98% Docetaxel (6) 91 ± 14 + 86 ± 3 +
LULI21 Lung Poorly differentiated SCC, 78% Docetaxel (6) 42 ± 16 −61 ± 29
LULI27 Lung Moderate-highly differentiated SCC, 80% Docetaxel (6) 115 ± 3 + 32 ± 11
LULI55 Lung Large cell carcinoma, 95% Docetaxel (6) 109 ± 1 + 14 ± 4
CTYW012 Lung Poor-moderately differentiated AC, 90% Gemzar + Cisplatin (7) 116 ± 0 + 84 ± 7 +
LULI49 Lung Poorly differentiated AC, 90% Erlotinib (8) 40 ± 15 −16 ± 26
CTC15063 Lung Poor-moderately differentiated AC, 95% Erlotinib (8) 37 ± 19 21 ± 17
CTC15063 Lung Poor-moderately differentiated AC, 95% AZD9291 (9) 167 ± 5 + 61 ± 3 +
CTC16075 Lung Poorly differentiated carcinoma, 90% Crizotinib (10) 103 ± 2 + 102 ± 4 +
PAYY8 Pancreas Poorly differentiated ductal AC, 90% Gemzar (11) 27 ± 27 −14 ± 10
PAYY5 Pancreas Poor-moderately differentiated ductal AC, 80% Gemzar (11) 75 ± 9 + 56 ± 8 +
PAYY5 Pancreas Poor-moderately differentiated ductal AC, 80% Oxaliplatin + Irinotecan (12) 112 ± 2 + 54 ± 6 +
  1. Model: Indicates a specific patient and patient-derived xenograft model
  2. Pathology: Judged by licensed pathologist (SY); %, percentage of the diseased cells judged by pathology; AC adenocarcinoma, SCC squamous cell carcinoma
  3. Regimen: Drug combinations used to test efficacy in specific PDX model and MiniPDX
  4. Chemotherapeutic or targeted drug: Single or combination of drugs used in PDX assay and in MiniPDX
  5. TGI: Tumor growth inhibition or TCGI: tumor cell growth inhibition. N = 6, results are mean ± SEM. Mean TGI or TCGI ≥ 45% is defined as positive therapeutic response (+)